The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.
AIDS Vaccines
/ immunology
Adjuvants, Immunologic
/ pharmacology
Animals
B-Lymphocytes
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
Cyclic AMP Response Element-Binding Protein
/ immunology
Gene Expression
/ immunology
Genetic Vectors
/ immunology
HIV Antibodies
/ immunology
HIV Infections
/ immunology
HIV-1
/ immunology
Humans
Immunization
/ methods
Immunogenicity, Vaccine
/ immunology
Primates
/ immunology
Vaccination
/ methods
Viral Vaccines
/ immunology
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
22
05
2020
accepted:
30
07
2021
pubmed:
25
9
2021
medline:
13
10
2021
entrez:
24
9
2021
Statut:
ppublish
Résumé
Development of effective human immunodeficiency virus 1 (HIV-1) vaccines requires synergy between innate and adaptive immune cells. Here we show that induction of the transcription factor CREB1 and its target genes by the recombinant canarypox vector ALVAC + Alum augments immunogenicity in non-human primates (NHPs) and predicts reduced HIV-1 acquisition in the RV144 trial. These target genes include those encoding cytokines/chemokines associated with heightened protection from simian immunodeficiency virus challenge in NHPs. Expression of CREB1 target genes probably results from direct cGAMP (STING agonist)-modulated p-CREB1 activity that drives the recruitment of CD4
Identifiants
pubmed: 34556879
doi: 10.1038/s41590-021-01026-9
pii: 10.1038/s41590-021-01026-9
pmc: PMC8525330
mid: NIHMS1729434
doi:
Substances chimiques
AIDS Vaccines
0
ALVAC vaccine
0
Adjuvants, Immunologic
0
Cyclic AMP Response Element-Binding Protein
0
HIV Antibodies
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1294-1305Subventions
Organisme : NIAID NIH HHS
ID : U01 AI067854
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI100645
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144371
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
pubmed: 19843557
doi: 10.1056/NEJMoa0908492
Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671 (2006).
pubmed: 17109337
doi: 10.1086/508748
Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665 (2005).
pubmed: 15688278
doi: 10.1086/428404
Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
pubmed: 22475592
pmcid: 3371689
doi: 10.1056/NEJMoa1113425
Gottardo, R. et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE 8, e75665 (2013).
pubmed: 24086607
pmcid: 3784573
doi: 10.1371/journal.pone.0075665
Montefiori, D. C. et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431–441 (2012).
pubmed: 22634875
pmcid: 3392187
doi: 10.1093/infdis/jis367
Tomaras, G. D. et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl Acad. Sci. USA 110, 9019–9024 (2013).
pubmed: 23661056
pmcid: 3670311
doi: 10.1073/pnas.1301456110
Rolland, M. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417–420 (2012).
pubmed: 22960785
pmcid: 3551291
doi: 10.1038/nature11519
Pegu, P. et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV
pubmed: 23175374
pmcid: 3554145
doi: 10.1128/JVI.02544-12
Vaccari, M. et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIV
pubmed: 27239761
pmcid: 5916782
doi: 10.1038/nm.4105
Vaccari, M. et al. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14
pubmed: 29785023
pmcid: 5992093
doi: 10.1038/s41591-018-0025-7
Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).
pubmed: 33761206
pmcid: 7888373
doi: 10.1056/NEJMoa2031499
Yu, Q. et al. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Vaccine 24, 6376–6391 (2006).
pubmed: 16859816
doi: 10.1016/j.vaccine.2006.06.011
Harenberg, A., Guillaume, F., Ryan, E. J., Burdin, N. & Spada, F. Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. Vaccine 26, 5004–5013 (2008).
pubmed: 18691624
pmcid: 7115550
doi: 10.1016/j.vaccine.2008.07.050
Mohan, T., Zhu, W., Wang, Y. & Wang, B. Z. Applications of chemokines as adjuvants for vaccine immunotherapy. Immunobiology 223, 477–485 (2018).
pubmed: 29246401
doi: 10.1016/j.imbio.2017.12.001
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 1239896
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Bracci, L., La Sorsa, V., Belardelli, F. & Proietti, E. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev. Vaccines 7, 373–381 (2008).
pubmed: 18393607
doi: 10.1586/14760584.7.3.373
Gaucher, D. et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119–3131 (2008).
pubmed: 19047440
pmcid: 2605227
doi: 10.1084/jem.20082292
Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116–125 (2009).
pubmed: 19029902
doi: 10.1038/ni.1688
Lachmann, A. et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438–2444 (2010).
pubmed: 20709693
pmcid: 2944209
doi: 10.1093/bioinformatics/btq466
Zhu, C. Y. et al. Cell growth suppression by thanatos-associated protein 11(THAP11) is mediated by transcriptional downregulation of c-Myc. Cell Death Differ. 16, 395–405 (2009).
pubmed: 19008924
doi: 10.1038/cdd.2008.160
Horb, M. E. & Thomsen, G. H. Tbx5 is essential for heart development. Development 126, 1739–1751 (1999).
pubmed: 10079235
doi: 10.1242/dev.126.8.1739
Offield, M. F. et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122, 983–995 (1996).
pubmed: 8631275
doi: 10.1242/dev.122.3.983
Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. & Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812–821 (1993).
pubmed: 8491378
doi: 10.1101/gad.7.5.812
Delaloye, J. et al. Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins. J. Virol. 89, 3819–3832 (2015).
pubmed: 25609807
pmcid: 4403427
doi: 10.1128/JVI.03061-14
Roth, V. The generalized LASSO. IEEE Trans. Neural Netw. 15, 16–28 (2004).
pubmed: 15387244
doi: 10.1109/TNN.2003.809398
Ancuta, P. et al. Fractalkine preferentially mediates arrest and migration of CD16
pubmed: 12810688
pmcid: 2193954
doi: 10.1084/jem.20022156
Ogilvie, P., Paoletti, S., Clark-Lewis, I. & Uguccioni, M. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102, 789–794 (2003).
pubmed: 12689946
doi: 10.1182/blood-2002-09-2773
Waskow, C. et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9, 676–683 (2008).
pubmed: 18469816
pmcid: 2746085
doi: 10.1038/ni.1615
Xu, D. et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur. J. Immunol. 30, 3147–3156 (2000).
pubmed: 11093129
doi: 10.1002/1521-4141(200011)30:11<3147::AID-IMMU3147>3.0.CO;2-J
Tassi, I. et al. The NF-κB regulator Bcl-3 governs dendritic cell antigen presentation functions in adaptive immunity. J. Immunol. 193, 4303–4311 (2014).
pubmed: 25246497
doi: 10.4049/jimmunol.1401505
Gringhuis, S. I., Kaptein, T. M., Wevers, B. A., Mesman, A. W. & Geijtenbeek, T. B. Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKKε- and CYLD-dependent Bcl3 activation. Nat. Commun. 5, 3898 (2014).
pubmed: 24867235
doi: 10.1038/ncomms4898
Redmond, W. L., Ruby, C. E. & Weinberg, A. D. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29, 187–201 (2009).
pubmed: 19538134
pmcid: 3180959
doi: 10.1615/CritRevImmunol.v29.i3.10
Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008).
pubmed: 2804933
pmcid: 2804933
doi: 10.1038/nature07317
Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
pubmed: 19776740
pmcid: 4664154
doi: 10.1038/nature08476
Ahn, J., Gutman, D., Saijo, S. & Barber, G. N. STING manifests self DNA-dependent inflammatory disease. Proc. Natl Acad. Sci. USA 109, 19386–19391 (2012).
pubmed: 23132945
pmcid: 3511090
doi: 10.1073/pnas.1215006109
Sahoo, A. et al. Stat6 and c-Jun mediate Th2 cell-specific IL-24 gene expression. J. Immunol. 186, 4098–4109 (2011).
pubmed: 21357535
doi: 10.4049/jimmunol.1002620
Tamada, K. et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164, 4105–4110 (2000).
pubmed: 10754304
doi: 10.4049/jimmunol.164.8.4105
Kearney, C. J., Randall, K. L. & Oliaro, J. DOCK8 regulates signal transduction events to control immunity. Cell Mol. Immunol. 14, 406–411 (2017).
pubmed: 28366940
pmcid: 5423093
doi: 10.1038/cmi.2017.9
Fulcher, J. A. et al. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J. Biol. Chem. 284, 26860–26870 (2009).
pubmed: 19635795
pmcid: 2785374
doi: 10.1074/jbc.M109.037507
Wang, M., Zhao, Y. & Zhang, B. Efficient test and visualization of multi-set intersections. Sci. Rep. 5, 16923 (2015).
pubmed: 26603754
pmcid: 26603754
doi: 10.1038/srep16923
Guo, H. et al. NLRX1 sequesters STING to negatively regulate the interferon response, thereby facilitating the replication of HIV-1 and DNA viruses. Cell Host Microbe 19, 515–528 (2016).
pubmed: 27078069
pmcid: 4833116
doi: 10.1016/j.chom.2016.03.001
Gao, D. et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341, 903–906 (2013).
pubmed: 23929945
pmcid: 23929945
doi: 10.1126/science.1240933
Marcus, A. et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 49, 754–763 (2018).
pubmed: 30332631
pmcid: 6488306
doi: 10.1016/j.immuni.2018.09.016
Zaal, A. et al. Anaphylatoxin C5a regulates 6-sulfo-LacNAc dendritic cell function in human through crosstalk with Toll-like receptor-induced CREB signaling. Front. Immunol. 8, 818 (2017).
pubmed: 28769928
pmcid: 5509794
doi: 10.3389/fimmu.2017.00818
Moser, B., Wolf, M., Walz, A. & Loetscher, P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75–84 (2004).
pubmed: 15102366
doi: 10.1016/j.it.2003.12.005
Liu, Q. H. et al. Expression and a role of functionally coupled P2Y receptors in human dendritic cells. FEBS Lett. 445, 402–408 (1999).
pubmed: 10094497
doi: 10.1016/S0014-5793(99)00161-1
Hara, S., Mizukami, H., Kuriiwa, F. & Mukai, T. cAMP production mediated through P2Y
pubmed: 21777648
doi: 10.1016/j.tox.2011.07.001
Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449–12463 (2008).
pubmed: 18842730
pmcid: 2593361
doi: 10.1128/JVI.01708-08
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
pubmed: 23323831
pmcid: 23323831
doi: 10.1186/1471-2105-14-7